secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001714899-25-000104
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali completes BLA submission for Hunter syndrome; Q1 net loss widens to $133M
--------------------------------------------------------------------------------

- Net loss of $133.0M in Q1 2025 vs $101.8M in Q1 2024; R&D expense rose to $116.2M.
- Cash and marketable securities $1.05B as of March 31, 2025.
- BLA for tividenofusp alfa (Hunter syndrome) submitted under FDA accelerated approval pathway.
- Phase 2b LUMA study for BIIB122 (Parkinson's) fully enrolled; readout expected in 2026.
- G&A expenses increased to $29.4M from $25.2M, driven by BLA submission and launch prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000104/0001714899-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000104/dnli-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer